Maxcyte, INC. (MXCT) — 10-Q Filings

All 10-Q filings from Maxcyte, INC.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (4)

MaxCyte Revenue Plunges 16% Amid Widening Losses, Cash Burn Accelerates — Nov 13, 2025 Risk: high
MaxCyte, Inc. reported a significant decline in revenue and an increased net loss for the three and nine months ended September 30, 2025. Revenue for the three
MaxCyte's Q2 Loss Widens Amidst Revenue Dip — Aug 6, 2025 Risk: high
MAXCYTE, INC. reported a net loss of $17.2 million for the three months ended June 30, 2025, a significant increase from the $14.5 million net loss in the prior
MaxCyte, Inc. Files Q1 2025 10-Q — May 8, 2025 Risk: low
MaxCyte, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including common stock and retained earnings as of
MaxCyte, Inc. Files Q2 2024 10-Q Report — Aug 6, 2024 Risk: medium
MaxCyte, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operations. Ke

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX